Acarbose: Clinical Trials

15 trials of Acarbose, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

11 completed, 2 terminated, 2 unknown. 15 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 315Completed 11, Terminated 2, Unknown 2

Follow Acarbose: new trials by email Literature Review of Acarbose trials Research Report on Acarbose

Trials (filtered) newest first · largest first

All 15 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Effect of Acarbose and Mixture of Pioglitazone and Metformin in Patients With Type 2 Diabetes
Metformin plus pioglitazone, Acarbose - Type 2 Diabetes, Blood Glucose Fluctuation
Phase 3UnknownNanjing First Hospital, Nanjing Medical University502022-04-102022-11-29
Acarbose and Prandial Insulin for the Treatment of Gestational Diabetes Mellitus.
Acarbose, Prandial insulin - Gestational Diabetes Mellitus in Pregnancy
Phase 3TerminatedAssistance Publique - Hôpitaux de Paris3412018-07-042024-07-03
Loose-dose Combination of Acarbose and Metformin for T2DM in Metformin-failure Patients
Acarbose, Metformin, Placebo - Diabetes Mellitus, Type 2
Phase 3CompletedBayer2872018-03-052020-08-05
Combining Saxagliptin and Acarbose to Improve Postprandial Glycaemia in Type 2 Diabetes
Saxagliptin, Acarbose - Type 2 Diabetes
Phase 3CompletedZilin Sun222015-04-032018-07-06
A Study to Assess the Efficacy and Safety of ASP1941 in Asian Subjects With Type 2 Diabetes Mellitus
ASP1941, acarbose, Placebo - Type II Diabetes Mellitus
Phase 3TerminatedAstellas Pharma Inc462012-04-232024-11-12
Clinical Trial to Evaluate the Safety and Efficacy of the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus Receiving Acarbose Monotherapy (MK-0431-130)
Sitagliptin phosphate, Comparator: Placebo, Acarbose - Type 2 Diabetes Mellitus
Phase 3CompletedMerck Sharp & Dohme LLC3802011-01-252018-08-16
A Phase III Randomized, Double-blind, Parallel-group Study to Evaluate the Efficacy and Safety of Acarmet (Metformin HCl 500 mg Plus Acarbose 50 mg Tablets) Versus Acarbose Alone in Subjects With Type 2 Diabetes Mellitus
Acarbose, Metformin/Acarbose - The Objectives of the Study is to Evaluate the Efficacy and Safety of Acarmet (Metformin HCl 500 mg, Plus Acarbose 50 mg Tablets) Thrice Daily Versus Acarbose 50 mg Thrice Daily Over 16 Weeks in
Phase 3UnknownLotus Pharmaceutical2202010-11-012010-11-22
A Study to Assess the Safety and Efficacy of ASP1941 in Combination With α-glucosidase Inhibitor in Type 2 Diabetic Patients
ipragliflozin, alpha glucosidase inhibitor - Type 2 Diabetes Mellitus
Phase 3CompletedAstellas Pharma Inc1132010-10-212025-05-30
Vildagliptin and Endothelium-dependent Vasodilatation
vildagliptin + acarbose, acarbose + vildagliptin - Type 2 Diabetes, Endothelial Dysfunction
Phase 3CompletedRadboud University Medical Center162010-01-012010-11-05
Effects of Acarbose on Endothelial Function After a Mixed Meal in Newly Diagnosed Type 2 Diabetes
acarbose, placebo - Type 2 Diabetes
Phase 3CompletedTechnische Universität Dresden2006-07-012013-03-01
Acarbose and Secondary Prevention After Coronary Stenting
Acarbose - Glucose Metabolism Disorders, Coronary Artery Disease
Phase 3CompletedTranslational Research Center for Medical Innovation, Kobe, Hyogo, Japan3002005-05-012009-06-25
AI(I)DA Acarbose and the Subclinical Inflammation
acarbose - Type 2 Diabetes Mellitus, Subclinical Inflammation
Phase 3CompletedGWT-TUD GmbH1042005-01-012008-04-11
Prevent/Delay Development of Type 2 Diabetes in Subjects With Impaired Glucose Homeostasis Treated With Acarbose in Primary Care
Acarbose (Glucobay, BAYG5421), Placebo - Diabetes Mellitus
Phase 3CompletedBayer2042000-08-012010-12-28
Action to Control Cardiovascular Risk in Diabetes (ACCORD)
Anti-hyperglycemic Agents, Anti-hypertensive Agents, Blinded fenofibrate or placebo plus simvastatin - Atherosclerosis, Cardiovascular Diseases
Phase 3CompletedNational Heart, Lung, and Blood Institute (NHLBI)102511999-09-012016-11-22
Metabolic Syndrome Risk Factor in IGT: STOP-NIDDM Trial
acarbose, placebo - Metabolic Syndrome
Phase 3CompletedGWT-TUD GmbH14292008-03-07

Conditions studied

Diabetes Mellitus, Type 2 (11)  ·  Diabetes Mellitus (5)  ·  Atherosclerosis (1)  ·  Cardiovascular Diseases (1)  ·  Coronary Artery Disease (1)  ·  Coronary Disease (1)  ·  Glucose Intolerance (1)  ·  Glucose Metabolism Disorders (1)  ·  Glycosuria (1)  ·  Hypercholesterolemia (1)  ·  Hypertension (1)  ·  Metabolic Diseases (1)  ·  Metabolic Syndrome (1)

Sponsors

Astellas Pharma Inc (2)  ·  Bayer (2)  ·  GWT-TUD GmbH (2)  ·  Assistance Publique - Hôpitaux de Paris (1)  ·  Lotus Pharmaceutical (1)  ·  Merck Sharp & Dohme LLC (1)  ·  Nanjing First Hospital, Nanjing Medical University (1)  ·  National Heart, Lung, and Blood Institute (NHLBI) (1)  ·  Radboud University Medical Center (1)  ·  Technische Universität Dresden (1)  ·  Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan (1)  ·  Zilin Sun (1)

Countries

China (3)  ·  Germany (2)  ·  Japan (2)  ·  Taiwan (2)  ·  Canada (1)  ·  France (1)  ·  Netherlands (1)  ·  South Korea (1)  ·  Spain (1)  ·  United States (1)

Top investigators

C.J. Tack, MD, PhD, Prof. of Diabetology (1)  ·  Denise Simons-Morton, MD, PhD (1)  ·  Koichi Tamita, MD. (1)  ·  Markolf Hanefeld, PhD (1)  ·  Markolf Hanefeld, PhD, MD (1)  ·  Minako Katayama, MD (1)  ·  Robert Byington, PhD (1)  ·  William Friedewald, MD (1)  ·  Yutaka Furukawa, MD (1)

Results publications

PMID 18539917, PMID 19156626, PMID 19898642, PMID 20061358, PMID 20061360, PMID 20215456, PMID 20228401, PMID 20228404, PMID 20427682, PMID 20571135, PMID 20587587, PMID 20594588, PMID 21366473, PMID 21663644, PMID 21958949, PMID 22019270, PMID 22049171, PMID 22179956, PMID 22374637, PMID 22432114, PMID 22450889, PMID 22515638, PMID 22619083, PMID 22646230, PMID 22723577, PMID 23033246, PMID 23238658, PMID 23412077, PMID 23990163, PMID 23993469, PMID 24170759, PMID 24296848, PMID 24485397, PMID 24493100, PMID 24595629, PMID 24779562, PMID 25088437, PMID 25127725, PMID 25159234, PMID 25172198, PMID 25193529, PMID 25229335, PMID 25267796, PMID 25652389, PMID 25666468, PMID 25887355, PMID 26261902, PMID 26459421, PMID 26464212, PMID 26476086

NIH funding

N01HC95178 (1), N01HC95179 (1), N01HC95180 (1), N01HC95181 (1), N01HC95182 (1), N01HC95183 (1), N01HC95184 (1)